GLP-1 Consumer Subscription Funnel

The key unlock in the GLP-1 wrapper is that obesity treatment turned into a consumer subscription funnel, not a traditional clinic. Demand got large enough that a company could buy traffic, move patients through a short intake and clinician review flow, ship monthly medication, and scale revenue much faster than staff. That is why businesses like AIOS jumped from near zero to tens of millions in annualized revenue once lower cost compounded supply became available and GLP-1 use spread broadly.1 2 3 4

• What the wrapper actually sells is convenience and access. The patient sees an ad, fills out a form in minutes, gets reviewed by a licensed prescriber, then receives ongoing shipments and dose changes without hunting for a doctor or local pharmacy. That simple workflow made GLP-1s much easier to buy than normal weight care.1 2
• This model grew fastest because the drug did the hard part. Older consumer health categories like coaching or supplements had to persuade people to stick with behavior change. GLP-1 wrappers sit on top of a product patients already want, so growth depends more on media buying and checkout conversion than on building a large care team.1 5 6
• The catch is that wrappers do not control the underlying molecule. When FDA said the semaglutide shortage was resolved in February 2025, the compounding window narrowed, and AIOS revenue fell from $82M annualized in March 2025 to $54M in September 2025. Eli Lilly also sued several telehealth sellers including Mochi Health and Henry Meds.1 3 7 8

Going forward, the best GLP-1 wrappers will look less like lightweight telehealth brands and more like distribution machines with pharmacy control, branded drug supply, and cross border expansion. The prize is keeping the fast consumer acquisition loop while moving closer to the prescription, dispensing, and eventually manufacturing economics that hold the real margin.1 3 9